BTG’s “Sell” Rating Reaffirmed at N+1 Singer (BTG)
BTG (LON:BTG)‘s stock had its “sell” rating restated by research analysts at N+1 Singer in a report released on Wednesday, Stock Ratings Network reports. They currently have a GBX 490 ($8.07) target price on the stock. N+1 Singer’s price target suggests a potential downside of 19.08% from the company’s current price.
A number of other firms have also recently commented on BTG. Analysts at Nplus1 Brewin reiterated a “sell” rating on shares of BTG in a research note to investors on Wednesday. They now have a GBX 490 ($8.07) price target on the stock. Separately, analysts at FinnCap reiterated a “sell” rating on shares of BTG in a research note to investors on Wednesday. They now have a GBX 345 ($5.68) price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of BTG in a research note to investors on Tuesday. They now have a GBX 630 ($10.38) price target on the stock. Three analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. BTG presently has a consensus rating of “Hold” and a consensus target price of GBX 524.78 ($8.65).
Shares of BTG (LON:BTG) opened at 595.00 on Wednesday. BTG has a one year low of GBX 313.70 and a one year high of GBX 624.00. The stock’s 50-day moving average is GBX 583.3 and its 200-day moving average is GBX 453.6.
BTG plc is an international specialist healthcare company. The Company is focused on three business areas: Specialty Pharmaceuticals, Interventional Medicine and Licensing & Biotechnology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.